This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Creative BioMart
product type :
antibody
product name :
Anti-VIM monoclonal antibody, clone FQS4887 [DyLight® 594]
catalog :
DCABH-3601
quantity :
100 μl
clonality :
monoclonal
host :
domestic rabbit
conjugate :
DyLight 594
clone name :
FQS4887
reactivity :
human
application :
immunocytochemistry
product information
Cat :
DCABH-3601
Product Name :
Anti-VIM monoclonal antibody, clone FQS4887 [DyLight® 594]
Brand :
Creative Diagnostics
Abbr :
Anti-VIM MAb, DyLight® 594-Conjugated
Host animal :
Rabbit
Clone :
FQS4887
Official Symbol :
VIM
Clonality :
Monoclonal
Application :
ICC/IF
Target :
VIM
Species Reactivity :
Human
Conjugate :
DyLight® 594
Antibody Type :
Primary Antibodies
Immunogen :
Synthetic acetylated peptide corresponding to the C-terminus of Human Vimentin (UniProt: P08670).
Alternative Names :
VIM; vimentin; FLJ36605;
UniProt ID :
P08670
Antibody Isotype :
IgG
Size :
100 μl
Storage :
Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. Store In the Dark.
company information
Creative BioMart
Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug development.
We are offering more than 3,000 recombinant proteins, peptides and antibodies. All the products are rigorously tested to meet the most demanding research needs. At the same time, lowest prices in the industry are always guaranteed.
Also, in order to leverage our core competencies and resources, Creative BioMart has formed a large number of corporate partnerships and academic collaborations for product development and distribution. We welcome potential partners and distributors to explore business relationships with Creative BioMart.
questions and comments